Back to search results

Zanubrutinib and Venetoclax in CLL (ZANU-VEN)

Abroad (travel likely)RecruitingPHASE2

Conditions

Chronic Lymphocytic Leukemia (CLL) · Small Lymphocytic Lymphoma (SLL)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • New England Cancer Specialists, Scarborough, Maine, United States

    Contact: Study coordinator (Patricia Collins) · collip@newecs.org · 207-303-3429
    Contact: Principal Investigator (John P Winters, III, MD)

  • Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

    Contact: Study coordinator (Jon Arnason, MD)
    Contact: Principal Investigator (Jon Arnason, MD)

  • Dana-Farber Cancer Institute, Boston, Massachusetts, United States

    Contact: Study coordinator (Inhye E Ahn, MD)
    Contact: Principal Investigator (Inhye E Ahn, MD)

  • South Shore Hospital, South Weymouth, Massachusetts, United States

    Contact: Study coordinator (Nicole Hixon, RN) · Nicole_Hixon@DFCI.HARVARD.EDU
    Contact: Principal Investigator (Nancy Kaddis, MD, MPH)
Study leads

  • Inhye E Ahn, MD

    Principal Investigator

    Dana-Farber Cancer Institute

View source on ClinicalTrials.gov(opens in a new tab)